BFM
ANIP icon

Boothbay Fund Management’s ANI Pharmaceuticals ANIP Stock Holding History

Boothbay Fund Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,200
Closed -$3.17M – 2233
2026
Q1 		$3.17M Buy
41,200
+18,600
+82% +$1.45M 0.04% 455
2025
Q4 		$1.78M Buy
+22,600
New +$1.96M 0.03% 597

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's ANIP Position: Q2 2026 in Review

Boothbay Fund Management increased its ANI Pharmaceuticals (ANIP) stake by 83% in Q2 2026, buying an estimated $2.7M and bringing the position to 74,368 shares worth $6.16M. The position accounts for 0.08% of the portfolio, ranked #286.

Boothbay Fund Management first reported a position in ANIP in Q4 2019 and has held it in 3 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Boothbay Fund Management held 74,368 shares of ANI Pharmaceuticals worth $6.16M as of Q2 2026.
  • Boothbay Fund Management bought 33,625 ANI Pharmaceuticals shares in Q2 2026, an estimated $2.7M.
  • ANI Pharmaceuticals made up 0.08% of Boothbay Fund Management's portfolio in Q2 2026, its #286 holding.
  • Boothbay Fund Management first reported a position in ANI Pharmaceuticals in Q4 2019 and has held it in 3 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.